Applied Dna Sciences (NASDAQ:BNBX) & Sagimet Biosciences (NASDAQ:SGMT) Head to Head ComparisonDefense World · Oct 16, 2026
BNB Plus Corp. Announces Strategic Shift to Institutional Technology Infrastructure for Blockchain and AI; Outlines Plan to Monetize AssetsBusiness Wire · Oct 2, 2026 Applied Dna Sciences (NASDAQ:BNBX) and Myriad Genetics (NASDAQ:MYGN) Head to Head AnalysisDefense World · Sep 28, 2026 Head-To-Head Comparison: Neurogene (NASDAQ:NGNE) & Applied Dna Sciences (NASDAQ:BNBX)Defense World · Sep 25, 2026
BNB Plus Corp. Appoints Three New Directors Identified Through Ongoing Strategic ReviewBusiness Wire · Sep 3, 2026
BNB Plus Corp. (BNBX) Announces Transition to Fully Internalized Digital Asset Treasury ManagementBusiness Wire · Jul 30, 2026BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production.